Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 31, 2016
Pharmacy Choice - News - Generic Drugs - August 31, 2016

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 85     Next >>     Go To Page:

8/31/16 - Cipla Receives Final Approval for Generic Wellbutrin XL Tablets
Cipla's Bupropion Hydrochloride Extended-Release Tablets, 150 mg and 300 mg, are ABrated generic equivalents of Valeant's Wellbutrin XL Tablets, 150 mg and 300 mg, and are indicated for the treatment of major depressive disorder and prevention of seasonal affective disorder. About Cipla Ltd. Cipla is a global pharmaceutical company which uses cutti
8/31/16 - EDITORIAL: Drugs costs need control [The Philadelphia Inquirer]
Aug. 31 It was bad enough pharmaceutical giant Mylan jacked up the price of the life-saving EpiPen from $100 to $600 since 2007, but when it announced this week it would sell an identical generic for $300, it underscored the maddening state of American health care. The pen makes a fortune for Mylan from Medicare and Medicaid as well as public sch
8/31/16 - EDITORIAL: To avoid drug price-gouging, speed approval of generics [The Salem News, Beverly, Mass.]
Today it sits around $600, having risen more than $200 in the last year alone. And it has, recalling last year's uproar when Turing Pharmaceuticals CEO Martin Shkreli raised the price of Daraprim, a key antibiotic in the treatment of HIV/AIDS, from $13.50 to $750 per tablet. It brought a predictable response from Congress.
8/31/16 - FDA approves Erelzi, a biosimilar to Enbrel
Release date- 30082016- The U.S. Food and Drug Administration today approved Erelzi, for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel, which was originally licensed in 1998.. 'The biosimilar pathway is an important mechanism to improve access to treatment for patients with rheumatic and autoimmune diseases,' said Janet Woodcock,
8/31/16 - FDA approves Sandoz Erelzi to treat multiple inflammatory diseases
Release date- 30082016- Holzkirchen- Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration approved Erelzi for all indications included in the reference product label, including rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and polyarticular..
8/31/16 - Impax Provides Update on Epinephrine Injection, USP Auto-Injector
Epinephrine Injection, USP Auto-Injector, 0.15 mg and 0.3 mg, the authorized generic to Adrenaclick, is currently available in pharmacies across the United States. 'With all the recent news related to epinephrine auto-injection products, we are increasing our mission to inform patients, caregivers and the professional community regarding the availa
8/31/16 - Indie Film to Finance Non-Profit Pharmaceutical Company
Career Opportunities in Organized Crime, an independent film released today, is set to put all proceeds towards the creation of a non-for-profit pharmaceutical company, "Osh's Not-for-Profit Pharmaceuticals." Osh's Not-for-Profit Pharmaceuticals is planning to take on these practices by producing cheap generic drugs with a 95%- 99% price reductio
8/31/16 - MedKart Asks Doctors to Shun Brands and Promote Generic Drugs
AHMEDABAD, India, August 31, 2016/ PRNewswire/. "Thanks to the strong lobby by the influential multi-national drug companies, which account for over 90 per cent of drug distribution in India, supported by doctors and medical stores, generic medicines still remain a far-cry for the poor in India. In the absence of accountability and stringent reg
8/31/16 - New Biologics Study Findings Recently Were Reported by Researchers at Amgen (Pharmacovigilance Considerations for Biosimilars in the USA)
By a News Reporter-Staff News Editor at Biotech Week New research on Biotechnology and Bioengineering- Biologics is the subject of a report. According to news originating from Longmont, Colorado, by NewsRx correspondents, research stated, "In 2015, five or more biosimilars may be approved in the USA. Our news journalists obtained a quote from the
8/31/16 - SOCMA's BPTF Pleased with Outcome of Round Two of Generic Drug User Fee Negotiations
WASHINGTON, Aug. 31, 2016/ PRNewswire-USNewswire/ The Bulk Pharmaceuticals Task Force, an affiliate of the Society of Chemical Manufacturers and Affiliates, today hailed the successful ending of negotiations for the reauthorization of the Food and Drug Administration's Generic Drug User Fee program. BPTF is a longtime stakeholder in the Generic D
8/30/16 - 20 Democratic senators blast steep price hike for EpiPens
The letter was addressed to Heather Bresch, CEO of the pharmaceutical company that makes the devices, Mylan N.V.. Joe Manchin, D- W.Va. Manchin did not sign the letter. Elizabeth Warren and other senators said the generic device still costs $300, three times more than the branded EpiPen did in 2007..
8/30/16 - AP Top Health News at 5:21 p.m. EDT
UN health revises advice for 3 infections transmitted by sex Mylan launching cheaper, generic version of EpiPen 20 Democratic senators blast steep price hike for EpiPens Playing with sports concussion doubles recovery time: Study Novartis wins US OK for biosimilar version of Amgen's Enbrel Clinton could face mounting problem with health overhaul He
8/30/16 - AP Top Health News at 5:48 p.m. EDT
UN health revises advice for 3 infections transmitted by sex Mylan launching cheaper, generic version of EpiPen 20 Democratic senators blast steep price hike for EpiPens Playing with sports concussion doubles recovery time: Study Novartis wins US OK for biosimilar version of Amgen's Enbrel Clinton could face mounting problem with health overhaul...
8/30/16 - AP Top Health News at 7:55 p.m. EDT
UN health revises advice for 3 infections transmitted by sex 20 Democratic senators blast steep price hike for EpiPens Lawyer investigating lead at Indiana housing complex Novartis wins US OK for biosimilar version of Amgen's Enbrel Health commissioner: State acted properly on tainted water Mylan launching cheaper, generic version of EpiPen Playing
8/30/16 - AUROBINDO, INTAS SEEK TO BOOST EUROPE BIZ
Pharmaceutical companies Aurobindo Pharmaceuticals of Hyderabad and Intas Pharmaceuticals of Gujarat are aiming to boost their businesses in Europe by acquiring the generic drugs of Teva Pharmaceuticals of Israel in Britain.
8/30/16 - Blumenthal Says Mylan Must Make EpiPen Cheaper [The Hartford Courant]
Aug. 30 Amid a growing controversy over drug costs, U.S. Sen. Drug manufacturer Mylan Pharmaceuticals Inc. said Monday it will offer a generic version of EpiPen that would cut the price to $300 for a two-pack. He also called for investigations by both the Senate judiciary and commerce committees, which could hold public hearings when Congress ret
8/30/16 - Branded Generics Market Value Chain and Forecast 2016-2026
Branded generics differ from commodity generics which are pharmaceutical products, generally used as an alternative to innovator product after the expiry of the patent.Valley Cottage, NY 08/30/2016 Branded generics are the drugs which are biosimilars to the innovator products and marketed under different brand names. In other words, bra
8/30/16 - Delivery Of Cancer Drugs, Medicines General, Albumin For Hospital Pharmacies Holy Cross Cancer Center In Kielce. [TendersInfo (India)]
Contract notice: Delivery of cancer drugs, medicines general, albumin for hospital pharmacies holy cross cancer center in kielce. The contract is for the purchase with the delivery of cancer drugs, generic drugs and drugs used in anesthesia for Hospital Pharmacies Holy Cross Cancer Center in Kielce according to Package No. 1: Pegfilgrastimum.
8/30/16 - Dr. Reddy's Laboratories launches Nitroglycerin sublingual tablets USP in the U.S. Market
Release date- 29082016- Hyderabad, India and Princeton, NJ, USA- Dr. Reddy's Laboratories Ltd announced today that it has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat sublingual tablets in the US market on August 26, 2016, having been approved by the United States Fo
8/30/16 - Elite Announces Development and License Agreement with SunGen Pharma LLC [Daily News Egypt]
-Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into a Development and License Agreement with SunGen Pharma, LLC to collaborate to develop and commercialize four generic pharmaceutical products. For the twelve months ending June 30, 2016,
8/30/16 - FDA approves Erelzi, a biosimilar to Enbrel
The U.S. Food and Drug Administration today approved Erelzi, for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel, which was originally licensed in 1998.. "The biosimilar pathway is an important mechanism to improve access to treatment for patients with rheumatic and autoimmune diseases," said Janet Woodcock, M.D., director of the
8/30/16 - FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases
Novartis International AG/ FDA approves Sandoz Erelzi (TM) to treat multiple inflammatory diseases. *Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine* Erelzi is approved for all indications included in the reference product's label* Erelzi is the second biosimilar from Sandoz to rece
8/30/16 - Global Biosimilars Market 2016-2020 - New Market Report
Fast Market Research announces the availability of the new TechNavio report, "Global Biosimilars Market 2016-2020", on their comprehensive research portalBoston, MA 08/30/2016 Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has
8/30/16 - GNW-News: FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases (english)
Novartis International AG/ FDA approves Sandoz Erelzi (TM) to treat multiple inflammatory diseases. *Erelzi is the second biosimilar from Sandoz to receive FDA approval in the. Holzkirchen, August 30, 2016- Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration approved Erelzi for
8/30/16 - Impax Provides Update on Epinephrine Injection, USP Auto-Injector
Impax Laboratories, Inc. today provided an update and additional information to patients, physicians and customers on its epinephrine injection, USP auto-injector, 0.15 mg and 0.3 mg., the authorized generic of Adrenaclick . "With all the recent news related to epinephrine auto-injection products, we are increasing our mission to inform patien
Articles(s): 1 - 25 of 85     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415